Teleflex Incorporated

NYSE:TFX

Medical - Instruments & Supplies

Healthcare
$165.85 +0.83%

+$1.04 today

Market cap
$6.58B
Beta
0.82
P/E (TTM)
-5.5
EPS (TTM)
-$22.79
Dividend yield
1.08%
52W Low $100.18High $139.67

Volume 1.16M

Average 0.80M

TFX EBITDA Margin

EBITDA as a percentage of revenue.

Teleflex IncorporatedNYSE: TFX

EBITDA Margin · Q2 FY2026 · quarter ended Jun 2026

EBITDA Margin narrows to 21.6%

EBITDA Margin was 21.6% in Q2 FY2026, down 7.0 pp from a year earlier. On a trailing-twelve-month basis it was -6.1%, down 25.9 pp year over year. Over 3 fiscal years it narrowed by 11.0 pp.

Context

  • EBITDA Margin widened in 1 of the last 3 fiscal years.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 9 analysts of 33.1% for the fiscal year ending Dec 2026, up from 15.2% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
21.6%+16.8 pp QoQ
Last fiscal yearDec 2025
15.2%+1.0 pp YoY
LTMJun 2026
-6.1%-25.9 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-7.0 pp+68.7 pp+75.7 pp
1 year+1.0 pp+17.9 pp+16.9 pp
3 years-11.0 pp+20.4 pp+31.4 pp
5 years+27.7 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
15.2%
Year-over-year change
+1.0pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How TFX compares with its peers on the latest reported figures

  • TFX's LTM Jun 2026 EBITDA Margin of -6.1% is the 8th highest of the 10 companies compared; the peer median is 17.2%.
  • Its year-over-year change of -25.9 pp is the 7th highest of 10, against a peer median of -2.8 pp.
  • Over three fiscal years its change of -11.0 pp compares with a peer median of +11.6 pp.
TFX Competitors Peer median
EBITDA Margin for TFX and competitors
Company Period LTM level YoY 3-year change
KRYSKrystal Biotech, Inc.LTM Jun 202649.9% -0.2 pp—
STVNStevanato Group S.p.A.LTM Jun 202624.3% -2.8 pp-0.4 pp
TGTXTG Therapeutics, Inc.LTM Sep 202621.3% -0.4 pp+7673.7 pp
MMSIMerit Medical Systems, Inc.LTM Sep 202621.2% -0.0 pp+6.2 pp
PTCTPTC Therapeutics, Inc.LTM Jun 202617.2% -30.5 pp+103.9 pp
BLCOBausch + Lomb CorporationLTM Jun 202613.9% +4.5 pp-5.4 pp
ALKSAlkermes plcLTM Sep 202610.2% -18.5 pp+17.0 pp
TFXTeleflex IncorporatedLTM Jun 2026-6.1% -25.9 pp-11.0 pp
ARWRArrowhead Pharmaceuticals, Inc.LTM Sep 2026-133.9% -153.8 pp-60.9 pp
CRSPCRISPR Therapeutics AGLTM Sep 2026-1917.5% -679.9 pp+127741.9 pp
PCVXVaxcyte, Inc.FY2025— ——
Peer median (excluding TFX) 17.2%-2.8 pp+11.6 pp

Competitors are the stored peer set for TFX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2.81B2.79B2.97B3.05B1.99B
Cost of Revenue1.26B1.26B1.33B1.34B871.96M
Gross Profit1.55B1.53B1.65B1.7B1.12B
Gross Margin55.2%54.9%55.4%55.9%56.2%
Research & Development130.84M153.82M154.35M161.67M144.78M
Selling, General & Admin860.09M863.75M929.87M995.27M720.17M
Operating Expenses921.51M1.03B1.14B1.55B864.95M
Depreciation & Amortization237.36M230.59M242.12M274.6M177.74M
EBITDA853.8M730.77M761.21M433.62M302.51M
EBITDA Margin30.4%26.2%25.6%14.2%15.2%
Operating Income628.1M499.73M506.31M151.01M255.8M
Operating Margin22.4%17.9%17.0%5.0%12.8%
Interest Income1.33M912K12.78M8.01M6.4M
Interest Expense56.97M54.26M85.08M83.54M100.22M
Other Income / Expenses(68.63M)(53.81M)(72.3M)(75.54M)(231.25M)
Income Before Tax559.47M445.92M434.01M75.48M24.55M
Pre-Tax Margin19.9%16.0%14.6%2.5%1.2%
Income Tax Expense74.35M83M76.44M5.32M(33.98M)
Net Income485.37M363.14M356.33M69.68M(905.64M)
Net Margin17.3%13.0%12.0%2.3%-45.4%
EPS (Basic)10.387.747.581.49(20.30)
EPS (Diluted)10.237.687.531.48(20.25)
Weighted Avg Shares46.77M46.9M46.98M46.84M44.62M
Weighted Avg Shares (Diluted)47.43M47.31M47.3M47.09M44.72M

Teleflex Incorporated

NYSE:TFX

Intrinsic Alpha fair value

Locked

Current Price

$165.85

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.